In this article
KING OF PRUSSIA, Pa., July 13, 2026. Proxa Labs, an AI-native commercial learning company for the biopharma industry, today announced its formal launch, introducing Intelligent Commercial Readiness (ICR): the discipline of ensuring a commercial organization's people are demonstrably capable of executing the business strategy, measured continuously and backed by evidence.
ICR inverts the model commercial learning has run on for three decades. Instead of delivering training and inferring capability from completions and certifications, the discipline measures what a field force can actually do against what a specific launch requires, and treats training as the targeted intervention that closes the gaps it finds. That inversion is the methodology at the foundation of everything Proxa Labs builds.
The launch of Proxa Labs comes at a moment where nearly every biopharma organization operates under an AI mandate without AI evidence. Proxa Labs was built to run experimentation before implementation to produce proof of business impact first, so organizations scale what works.
The company's technology follows the same logic. The platform is designed with AI as the foundation. It employs a closed-loop methodology where it detects where field capability is breaking down, generates the intervention to address it, and confirms the gap has closed.
Proxa Labs is ISO/IEC 42001 certified, the international standard for AI management systems, giving compliance organizations the same governance rigor over commercial AI that biopharma applies to its science.
"Commercial learning leaders are being handed AI mandates with no reliable way to execute them," said John Royer, Founder and Managing Partner of Proxa Labs. "This function has spent decades reporting activity and being treated as a cost center. AI finally gives it the means to prove impact and lead. The seat at the table is open. We built Proxa Labs to put learning leaders in it."
Proxa Labs differentiates by being advisory-first. Every engagement begins with a diagnosis of the organization's readiness posture, using the company's proprietary AI Readiness Maturity Model, before any recommendation is made.
"Most AI initiatives in this industry fail because pilots launch before anyone defines what success looks like," Royer added. "We do the opposite. Diagnose, experiment, prove, then scale. It costs a month up front and pays it back every month after."
Royer founded Proxa Labs after 25 years inside biopharma commercial learning, including global commercial learning leadership at AstraZeneca. He is a recipient of the Vanguard Award for Best Corporate Learning Program.
About Proxa Labs
Proxa Labs is an AI-native commercial learning company for the biopharma industry, built on the discipline of Intelligent Commercial Readiness. To learn more or begin with a readiness diagnosis, visit proxalabs.com.
